Meeting
2024 ASCO Genitourinary Cancers Symposium
Adverse outcomes (AOs) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with intensified androgen deprivation therapy (ADT+).
Authors
Nabiel Ali Mir
University of Chicago Medical Center, Chicago, IL
Nabiel Ali Mir , Waqaas Akmal , Maaz Imam , Mihai Giurcanu , Russell Zelig Szmulewitz , Walter Michael Stadler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 113)
DOI
10.1200/JCO.2024.42.4_suppl.113
Abstract #
113
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2023 ASCO Genitourinary Cancers Symposium
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.
First Author: Geoffrey T. Gotto
Poster
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
First Author: Martin W. Schoen
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay